Myriad Presents Fourth Study Showing Prolaris Score Predicts Prostate Cancer Aggressiveness | GenomeWeb

Myriad this week announced results from a study showing that the company's Prolaris assay accurately predicted elevated risk of prostate cancer recurrence in a cohort of men who had received radical prostatectomies.

Myriad conducted the study with researchers at the University of California, San Francisco, who presented the results last week at the 2012 Genitourinary Cancers Symposium in San Francisco.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.